Treatment with Enspryng (satralizumab) was associated with fewer attacks and improved disability scores among people with neuromyelitis optica…
Articles by Margarida Maia, PhD
In a real-world study of adults living with neuromyelitis optica spectrum disorder (NMOSD) in Japan, Uplizna (inebilizumab) was…
MIL62, an injection therapy approved exclusively in China for neuromyelitis optica spectrum disorder (NMOSD), was found to keep…
People with neuromyelitis optica spectrum disorder (NMOSD) often experience severe fatigue, pain, anxiety, and depression that are not fully…
For adults with neuromyelitis optica spectrum disorder (NMOSD), rituximab and Uplizna (inebilizumab) work equally well to prevent disease…
Therapies specifically approved by the U.S. Food and Drug Administration (FDA) for neuromyelitis optica spectrum disorder (NMOSD) are superior…
Add-on hyperbaric oxygen therapy (HBOT), which involves breathing pure oxygen at high pressure, may help reduce inflammation in people with…
A U.S.-based registry of adults with neuromyelitis optica spectrum disorder (NMOSD) shows that most patients are receiving biologic…
People with neuromyelitis optica spectrum disorder (NMOSD) are at a nine times higher risk of developing autoimmune rheumatic diseases,…
Rituximab and mycophenolate mofetil (MMF) may be the most effective off-label options for neuromyelitis optica spectrum disorder (NMOSD) patients…